A type III-A CRISPR-Cas Csm complex, comprising crRNA, Csm3, Csm4 or any other subunits, usage for the cleavage of target RNA containing a nucleotide sequence complementary to the crRNA bound in the complex. Provides methods for site-specific cleavage of target RNA molecules and RNA knock-down or RNA knock-out, in vitro or in vivo.
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